Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05639556

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies including evaluation of nutritional intervention. Further, the study will also include psychosocial and other patient-reported outcomes and medical contributors to understand their contributions to the nutritional failure in the adult advanced lung disease population. Finally, the study will evaluate both established and emerging nutritional and body composition parameters and link them to clinical outcomes in adults with CF across the spectrum of pulmonary function.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Arizona, Tucson, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cohort 1: Participants are eligible if their percentage of predicated forced expiratory volume in 1 second (ppFEV1) is <70% during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation)
  • Cohort 2: Participants are eligible if their percentage of predicted forced expiratory volume in 1 second (ppFEV1) is 70% or greater during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation).
  • Both cohorts match by age, gender, race and CFTR genotype severity.

Exclusion criteria

  • No prior solid organ transplantation
  • No initiation of an investigation drug within 28 days prior to and including Baseline Visit.
  • No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, Cayston, CFTR modulator, etc.) within 28 days prior to and including Baseline visit.
  • No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within 14 days prior to and including Baseline visit.
  • For the BIA sub-study - Individuals with an implanted pacemaker will be excluded.
  • No initiation of a drug for weight loss (such as a GLP-1 receptor agonist) or bariatric surgery within 6-months prior to and including the Baseline visit.
  • Patients with continued rapid change or extreme GI symptoms related to weight loss therapy should be excluded at the discretion of the study investigator.

Treatment and study plan

BMI and lean mass index from DXA

Diagnostic Test

Estimate and compare correlation between lean mass index from DXA and BMI

Anthropometric measurements

Diagnostic Test

Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.

Hand-grip strength

Diagnostic Test

A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.

Six-minute walk test

Diagnostic Test

This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.

Sit-to-Stand Test

Diagnostic Test

This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.

Short physical performance battery (SPPB)

Diagnostic Test

This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).

BIA Sub-study

Diagnostic Test

A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).

Accelerometry to assess physical activity

Diagnostic Test

Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.

Gastrointestinal (GI) and nutrition questionnaires:

Other

Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).

Psychosocial questionnaire: PHQ-8

Other

This is an 8-item scale that measures depressive symptoms over the past two weeks.

Psychosocial questionnaire: GAD-7

Other

This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.

Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)

Other

This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.

Psychosocial questionnaire: CF Fatalism Scale

Other

The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.

Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)

Other

The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.

12-month Questionnaire

Other

A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.

Oral glucose tolerance testing (OGTT)

Other

For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.

Continuous glucose monitoring (CGM)

Device

Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.

Chest CT scans (When available within the past 6 months in medical records)

Diagnostic Test

Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.

Hologic Dual X-Ray Absorptiometry (DXA)

Diagnostic Test

DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.

Ultrasound Sub-study of assessment of appendage muscles using ultrasound

Diagnostic Test

A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.

Psychosocial questionnaire: Hunger Vital Sign questionnaire

Diagnostic Test

Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.

Respiratory symptom questionnaire: CRISS

Other

Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.

Spirometry

Diagnostic Test

Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.

Psychosocial questionnaire: Additional Health Questionnaire

Other

Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.

CF Management Questionnaire

Other

Assessment of prior 12-month management of cystic fibrosis, including treatments, medication intake and hospitalizations. This questionnaire will only be completed at 24- and 36- month visits.

Food Frequency Questionnaire

Other

Assessment of prior 12-month nutritional intake being completed at Baseline (no later than 6-month visit) and 12-month visit.

Primary outcomes

  1. Correlation between DXA lean mass index and BMI

    Time frame: Baseline and 1 year

    Estimate and compare correlation between lean mass index from DXA (kg/m2) and BMI (kg/m2)

  2. Correlation between DXA lean mass index and mid-arm muscle circumference

    Time frame: Baseline and 1 year

    Estimate and compare correlation between lean mass index from DXA (kg/m2) and mid-arm muscle circumference (cm)

  3. Correlation between DXA lean mass index and hand-grip strength

    Time frame: Baseline and 1 year

    Estimate and compare correlation between lean mass index from DXA (kg/m2) and hand-grip strength (kg)

  4. Correlation between DXA lean mass index and the 6-minute walk distance traveled

    Time frame: Baseline and 1 year

    Estimate and compare correlation between lean mass index from DXA (kg/m2) and 6-minute walk (distance traveled in six minutes)

  5. Correlation between DXA lean mass index and the 1-minute sit-to-stand number of repetitions

    Time frame: Baseline and 1 year

    Estimate and compare correlation between lean mass index from DXA (kg/m2) and 1-minute sit-to-stand (number of sit-to-stand repetitions in one minute)

  6. Correlation between DXA lean mass index and Short Physical Performance Battery frailty score

    Time frame: Baseline and 1 year

    Estimate and compare correlation between lean mass index from DXA (kg/m2) and Short Physical Performance Battery frailty score (total points)

Secondary outcomes

  1. Characterize lean mass index from DXA cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize lean mass index from DXA cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  2. Characterize BMI cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize lean mass index from BMI cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  3. Characterize mid-arm measurement circumference cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize lean mass index from mid-arm circumference measurements cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  4. Characterize hand-grip strength cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize hand-grip strength cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  5. Characterize 1 minute sit-to-stand repetitions cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize the 1 minute sit-to-stand repetitions cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  6. Characterize mid-arm 6-minute walk test distance traveled cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize the 6-minute walk test distance traveled cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  7. Characterize the Short Physical Performance Battery frailty score cross-sectionally and longitudinally

    Time frame: Baseline and 1 year

    Characterize the Short Physical Performance Battery frailty score cross-sectionally (at enrollment) and longitudinally (post-enrollment changes) based on descriptive statistics and evaluate variance

  8. Compare lean mass index from DXA between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare lean mass index from DXA between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  9. Compare BMI between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare BMI between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  10. Compare lean mass index from mid-arm muscle circumference between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare lean mass index from mid-arm muscle circumference between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  11. Compare hand-grip strength between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare hand-grip strength between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  12. Compare the 1-minute sit-to-stand repetitions between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare the 1-minute sit-to-stand repetitions between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  13. Compare the 6-minute walk test distance between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare the 6-minute walk test distance between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  14. Compare the Short Physical Performance Battery frailty score between participants with FEV1 <70% to matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Compare the Short Physical Performance Battery frailty score between participants with FEV1 <70% to matched participants with FEV1 ≥70%.

  15. Evaluate mean glucose in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate mean glucose from continuous glucose measurement data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  16. Evaluate % time above 140 mg/dL in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate % time above 140 mg/dL from continuous glucose measurement data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  17. Evaluate % time above 180 mg/dL in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate % time above 180 mg/dL from continuous glucose measurement data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  18. Evaluate peak glucose in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate peak glucose from continuous glucose measurement data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  19. Evaluate % time below 70 mg/dL in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate % time below 70 mg/dL from continuous glucose measurement data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  20. Evaluate % time below 54 mg/dL in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate % time below 54 mg/dL from continuous glucose measurement data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  21. Evaluate the standard deviation in CGM glucose data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

    Time frame: Baseline and 1 year

    Evaluate the standard deviation in CGM glucose data in participants with FEV1 <70% and matched participants with FEV1 ≥70%

  22. Evaluate the coefficient of variation in CGM glucose data in participants with FEV1 <70% and matched participants with FEV1 ≥70% participants

    Time frame: Baseline and 1 year

    Evaluate the coefficient of variation in CGM glucose data in participants with FEV1 <70% and matched participants with FEV1 ≥70% participants

Sponsors and collaborators

Lead sponsor

Jaeb Center for Health Research

Other

Registry information

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Dec 6, 2022
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.